# Hyaluronic Acid and Sodium Hypochlorite as Adjunctive Therapeutic Options for Patients with Periodontal Disease: A Systematic Review

**Authors:** Tomás Infante da Câmara, Francisca Abreu, Miguel Nunes Vasques, Ricardo Faria-Almeida, Honorato Ribeiro-Vidal

PMC · DOI: 10.3390/biomedicines14020320 · Biomedicines · 2026-01-30

## TL;DR

This study finds that using hyaluronic acid and sodium hypochlorite alongside standard periodontal treatment improves outcomes like reduced gum pockets and better tissue attachment.

## Contribution

The study provides new evidence that combining hyaluronic acid and sodium hypochlorite with standard therapy improves periodontal outcomes.

## Key findings

- Adjunctive therapy with hyaluronic acid and sodium hypochlorite significantly reduced probing pocket depth.
- Clinical attachment level improved more with adjunctive treatment compared to standard therapy alone.
- Pocket closure rates were higher in deep pockets with the adjunctive treatment.

## Abstract

Background: Periodontal disease is a chronic multifactorial inflammatory condition caused by dysbiosis of the dental biofilm, leading to destruction of the connective tissue attachment, alveolar bone resorption, and potentially tooth loss. Non-surgical periodontal therapy (NSPT), involving subgingival instrumentation, aims to restore periodontal health by reducing the probing pocket depth (PPD) and bleeding on probing (BOP) and by improving the clinical attachment level (CAL). The adjunctive use of chemical agents, such as sodium hypochlorite/amino acids (NaOCl) and cross-linked hyaluronic acid (xHyA) gels, has been proposed to enhance the efficacy of NSPT. Objective: This systematic review aimed to evaluate the clinical effectiveness of the subgingival application of NaOCl and xHyA gels as adjunctive therapies to NSPT in patients with periodontal disease. Materials and Methods: A comprehensive literature search was conducted in the MEDLINE (PubMed), Cochrane Library, Web of Science, and Scopus databases following PRISMA guidelines. The review was registered in PROSPERO (CRD420251074045). Randomized clinical trials (RCTs) in human subjects with a follow-up of at least 6 months were included if they assessed outcomes such as PPD, CAL, BOP, or radiographic bone loss (RBL). Studies involving the adjunctive use of NaOCl and xHyA gels were selected according to the PICOS strategy. Results: Two RCTs published between 2023 and 2024, with follow-ups ranging from 6 to 9 months and involving 48–50 patients, met the inclusion criteria. Both studies demonstrated significant improvements in clinical outcomes when sodium hypochlorite and hyaluronic acid were used adjunctively with NSPT compared to when NSPT was used alone. Sites treated with adjunctive therapy showed significantly greater reductions in PPD and greater CAL gains over time. Pocket closure rates were also markedly higher in deep sites (>7 mm) in the adjunctive group than in the control group, indicating a substantial regenerative potential and a possible reduction in the need for surgical intervention. Gingival recession exhibited more favorable recovery trends in the adjunctive group, while BOP frequency decreased in both groups without statistically significant differences. Conclusions: The adjunctive use of NaOCl and xHyA gels in non-surgical periodontal therapy significantly enhances clinical outcomes compared with the use of mechanical debridement alone.

## Linked entities

- **Chemicals:** sodium hypochlorite (PubChem CID 23665760)
- **Diseases:** periodontal disease (MONDO:0002635)

## Full-text entities

- **Diseases:** peri-implantitis (MESH:D057873), resorption (MESH:D014091), mucositis (MESH:D052016), BOP (MESH:D006470), bone resorption (MESH:D001862), immune dysregulation (OMIM:614878), Periodontal Disease (MESH:D010510), attachment loss (MESH:D017622), gingival bleeding (MESH:D005884), PPD (MESH:D005888), Disease (MESH:D004194), injury to (MESH:D014947), inflammation (MESH:D007249), NSPT (MESH:D010518), tooth loss (MESH:D016388), GR (MESH:D005889), calculus (MESH:D002137), therapy[MeSH (MESH:D016609), dysbiosis (MESH:D064806), diabetes (MESH:D003920), CAL (MESH:D019962), REC (MESH:C565432), RBL (MESH:D001847), gingivitis[MeSH (MESH:D005891)
- **Chemicals:** Hyaluronic Acid (MESH:D006820), Perisolv (-), amino acid (MESH:D000596), NaOCl (MESH:D012973)
- **Species:** Prevotella intermedia (species) [taxon 28131], Fusobacterium nucleatum (species) [taxon 851], Porphyromonas gingivalis (species) [taxon 837], Aggregatibacter actinomycetemcomitans (species) [taxon 714], Treponema denticola (species) [taxon 158], Canis lupus familiaris (dog, subspecies) [taxon 9615], Homo sapiens (human, species) [taxon 9606], Tannerella forsythia (species) [taxon 28112]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12938360/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12938360/full.md

## References

70 references — full list in the complete paper: https://tomesphere.com/paper/PMC12938360/full.md

---
Source: https://tomesphere.com/paper/PMC12938360